Neisseria meningitidis and Escherichia coli are protected from leukocyte phagocytosis by binding to erythrocyte complement receptor 1 in human blood

Molecular Immunology

Volumn 48, Issue 15-16, 2011, Pages 2159-2169

  Brekke, Ole Lars ^a,b   Hellerud, Bernt Christian ^c   Christiansen, Dorte ^a   Fure, Hilde ^a   Castellheim, Albert ^c   Nielsen, Erik Waage ^a   Pharo, Anne ^c   Lindstad, Julie Katrine ^c   Bergseth, Grethe ^a   Leslie, Graham ^d   Lambris, John D ^e   Brandtzaeg, Petter ^c   Mollnes, Tom Eirik ^a,b,c  

^a NORDLAND HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

CR1; Erythrocytes; Phagocytes; Sepsis

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; BLOCKING AGENT; BLOCKING ANTIBODY; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C3B RECEPTOR BLOCKING MONOCLONAL ANTIBODY 3D9; COMPSTATIN; LEPIRUDIN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; BLOOD; COMPLEMENT INHIBITION; CONTROLLED STUDY; ERYTHROCYTE; ESCHERICHIA COLI; FLOW CYTOMETRY; GRANULOCYTE; HUMAN; IN VIVO STUDY; LEUKOCYTE; MONOCYTE; NEISSERIA MENINGITIDIS; NONHUMAN; OPSONIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; RESPIRATORY BURST;

ANIMALS; CELL SEPARATION; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTES; ESCHERICHIA COLI; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; LEUKOCYTES; NEISSERIA MENINGITIDIS; PHAGOCYTOSIS; RECEPTORS, COMPLEMENT 3B; RESPIRATORY BURST; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEPSIS; SWINE;

ALEXA; BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; NEGIBACTERIA; NEISSERIA MENINGITIDIS; PRIMATES; SUIDAE;

EID: 80051939830     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2011.07.011     Document Type: Article

References (52)

1. Benacerraf B., Sebestyen M.M., Schlossman S. A quantitative study of the kinetics of blood clearance of P32-labelled Escherichia coli and Staphylococci by the reticuloendothelial system. J. Exp. Med. 1959, 110:27-48.
2. Beynon H.L., Davies K.A., Haskard D.O., Walport M.J. Erythrocyte complement receptor type 1 and interactions between immune complexes, neutrophils, and endothelium. J. Immunol. 1994, 153:3160-3167.
3. Birmingham D.J., Hebert L.A. CR1 and CR1-like: the primate immune adherence receptors. Immunol. Rev. 2001, 180:100-111.
4. Brandtzaeg P., Mollnes T.E., Kierulf P. Complement activation and endotoxin levels in systemic meningococcal disease. J. Infect. Dis. 1989, 160:58-65.
5. Brekke O.L., Christiansen D., Fure H., Fung M., Mollnes T.E. The role of complement C3 opsonization, C5a receptor, and CD14 in E. coli-induced up-regulation of granulocyte and monocyte CD11b/CD18 (CR3), phagocytosis, and oxidative burst in human whole blood. J. Leukoc. Biol. 2007, 81:1404-1413.
6. Castellheim A., Brekke O.L., Espevik T., Harboe M., Mollnes T.E. Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis. Scand. J. Immunol. 2009, 69:479-491.
7. Castellheim A., Thorgersen E.B., Hellerud B.C., Pharo A., Johansen H.T., Brosstad F., Gaustad P., Brun H., Fosse E., Tonnessen T.I., Nielsen E.W., Mollnes T.E. New biomarkers in an acute model of live Escherichia coli-induced sepsis in pigs. Scand. J. Immunol. 2008, 68:75-84.
8. Cooper N.R. Immune adherence by the fourth component of complement. Science 1969, 165:396-398.
9. Cornacoff J.B., Hebert L.A., Smead W.L., Van Aman M.E., Birmingham D.J., Waxman F.J. Primate erythrocyte-immune complex-clearing mechanism. J. Clin. Invest. 1983, 71:236-247.
10. DiStasi M.R., Ley K. Opening the flood-gates: how neutrophil-endothelial interactions regulate permeability. Trends Immunol. 2009, 30:547-556.
11. Duke H.L., Wallace J.M. " Red cell adhesion" in trypanosmiasis of man and animals. Parasitology 1930, 22:414-456.
12. Fearon D.T. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc. Natl. Acad. Sci. U.S.A. 1979, 76:5867-5871.
13. Ghiran I., Barbashov S.F., Klickstein L.B., Tas S.W., Jensenius J.C., Nicholson-Weller A. Complement receptor 1/CD35 is a receptor for mannan-binding lectin. J. Exp. Med. 2000, 192:1797-1808.
14. Ghiran I., Glodek A.M., Weaver G., Klickstein L.B., Nicholson-Weller A. Ligation of erythrocyte CR1 induces its clustering in complex with scaffolding protein FAP-1. Blood 2008, 112:3465-3473.
15. Hirakata Y., Tomono K., Tateda K., Matsumoto T., Furuya N., Shimoguchi K., Kaku M., Yamaguchi K. Role of bacterial association with Kupffer cells in occurrence of endogenous systemic bacteremia. Infect. Immun. 1991, 59:289-294.
16. Holten E. Serotypes of Neisseria meningitidis isolated from patients in Norway during the first six months of 1978. J. Clin. Microbiol. 1979, 9:186-188.
17. Hourcade D.E. The role of properdin in the assembly of the alternative pathway C3 convertases of complement. J. Biol. Chem. 2006, 281:2128-2132.
18. Iida K., Nussenzweig V. Complement receptor is an inhibitor of the complement cascade. J. Exp. Med. 1981, 153:1138-1150.
19. Jack D.L., Lee M.E., Turner M.W., Klein N.J., Read R.C. Mannose-binding lectin enhances phagocytosis and killing of Neisseria meningitidis by human macrophages. J. Leukoc. Biol. 2005, 77:328-336.
20. Katragadda M., Magotti P., Sfyroera G., Lambris J.D. Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J. Med. Chem. 2006, 49:4616-4622.
21. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010, 11:373-384.
22. Klein A., Zhadkewich M., Margolick J., Winkelstein J., Bulkley G. Quantitative discrimination of hepatic reticuloendothelial clearance and phagocytic killing. J. Leukoc. Biol. 1994, 55:248-252.
23. Krych M., Hourcade D., Atkinson J.P. Sites within the complement C3b/C4b receptor important for the specificity of ligand binding. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:4353-4357.
24. Lappegard K.T., Riesenfeld J., Brekke O.L., Bergseth G., Lambris J.D., Mollnes T.E. Differential effect of heparin coating and complement inhibition on artificial surface-induced eicosanoid production. Ann. Thorac. Surg. 2005, 79:917-923.
25. Lee H., Whitfeld P.L., Mackay C.R. Receptors for complement C5a. The importance of C5aR and the enigmatic role of C5L2. Immunol. Cell Biol. 2008, 86:153-160.
26. Lewis L.A., Ram S., Prasad A., Gulati S., Getzlaff S., Blom A.M., Vogel U., Rice P.A. Defining targets for complement components C4b and C3b on the pathogenic neisseriae. Infect. Immun. 2008, 76:339-350.
27. Li J., Wang J.P., Ghiran I., Cerny A., Szalai A.J., Briles D.E., Finberg R.W. Complement receptor 1 expression on mouse erythrocytes mediates clearance of Streptococcus pneumoniae by immune adherence. Infect. Immun. 2010, 78:3129-3135.
28. Martin G.S., Mannino D.M., Eaton S., Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 2003, 348:1546-1554.
29. Mastellos D., Papadimitriou J.C., Franchini S., Tsonis P.A., Lambris J.D. A novel role of complement: mice deficient in the fifth component of complement (C5) exhibit impaired liver regeneration. J. Immunol. 2001, 166:2479-2486.
30. Matsushita M., Fujita T. The role of ficolins in innate immunity. Immunobiology 2002, 205:490-497.
31. Medof M.E., Iida K., Mold C., Nussenzweig V. Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes. J. Exp. Med. 1982, 156:1739-1754.
32. Mollnes T.E., Brekke O.L., Fung M., Fure H., Christiansen D., Bergseth G., Videm V., Lappegard K.T., Kohl J., Lambris J.D. Essential role of the C5a receptor in E. coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 2002, 100:1869-1877.
33. Mollnes T.E., Kirschfink M. Strategies of therapeutic complement inhibition. Mol. Immunol. 2006, 43:107-121.
34. Mollnes T.E., Lea T., Froland S.S., Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand. J. Immunol. 1985, 22:197-202.
35. Nelson R.A. The immune-adherence phenomenon; an immunologically specific reaction between microorganisms and erythrocytes leading to enhanced phagocytosis. Science 1953, 118:733-737.
36. Newman S.L., Mikus L.K. Deposition of C3b and iC3b onto particulate activators of the human complement system, Quantitation with monoclonal antibodies to human C3. J. Exp. Med. 1985, 161:1414-1431.
37. Nielsen C.H., Svehag S.E., Marquart H.V., Leslie R.G. Interactions of opsonized immune complexes with whole blood cells: binding to erythrocytes restricts complex uptake by leucocyte populations. Scand. J. Immunol. 1994, 40:228-236.
38. Nielsen E.W., Hellerud B.C., Thorgersen E.B., Castellheim A., Pharo A., Lindstad J., Tonnessen T.I., Brandtzaeg P., Mollnes T.E. A new dynamic porcine model of meningococcal shock. Shock 2009, 32:302-309.
39. O'Shea J.J., Brown E.J., Seligmann B.E., Metcalf J.A., Frank M.M., Gallin J.I. Evidence for distinct intracellular pools of receptors for C3b and C3bi in human neutrophils. J. Immunol. 1985, 134:2580-2587.
40. Ovstebo R., Brandtzaeg P., Brusletto B., Haug K.B., Lande K., Hoiby E.A., Kierulf P. Use of robotized DNA isolation and real-time PCR to quantify and identify close correlation between levels of Neisseria meningitidis DNA and lipopolysaccharides in plasma and cerebrospinal fluid from patients with systemic meningococcal disease. J. Clin. Microbiol. 2004, 42:2980-2987.
41. Paccaud J.P., Carpentier J.L., Schifferli J.A. Direct evidence for the clustered nature of complement receptors type 1 on the erythrocyte membrane. J. Immunol. 1988, 141:3889-3894.
42. Paccaud J.P., Carpentier J.L., Schifferli J.A. Difference in the clustering of complement receptor type 1 (CR1) on polymorphonuclear leukocytes and erythrocytes: effect on immune adherence. Eur. J. Immunol. 1990, 20:283-289.
43. Parrish W.R., Gallowitsch-Puerta M., Czura C.J., Tracey K.J. Experimental therapeutic strategies for severe sepsis: mediators and mechanisms. Ann. N.Y. Acad. Sci. 2008, 1144:210-236.
44. Ross G.D., Jarowski C.I., Rabellino E.M., Winchester R.J. The sequential appearance of Ia-like antigens and two different complement receptors during the maturation of human neutrophils. J. Exp. Med. 1978, 147:730-744.
45. Schifferli J.A., Ng Y.C., Estreicher J., Walport M.J. The clearance of tetanus toxoid/anti-tetanus toxoid immune complexes from the circulation of humans, Complement- and erythrocyte complement receptor 1-dependent mechanisms. J. Immunol. 1988, 140:899-904.
46. Silasi-Mansat R., Zhu H., Popescu N.I., Peer G., Sfyroera G., Magotti P., Ivanciu L., Lupu C., Mollnes T.E., Taylor F.B., Kinasewitz G., Lambris J.D., Lupu F. Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood 2010, 116:1002-1010.
47. Sprong T., Brandtzaeg P., Fung M., Pharo A.M., Hoiby E.A., Michaelsen T.E., Aase A., van der Meer J.W., van Deuren M., Mollnes T.E. Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis. Blood 2003, 102:3702-3710.
48. Steeghs L., de C.H., Evers E., Zomer B., Tommassen J., van der L.P. Outer membrane composition of a lipopolysaccharide-deficient Neisseria meningitidis mutant. EMBO J. 2001, 20:6937-6945.
49. Stephens D.S., Greenwood B., Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007, 369:2196-2210.
50. Thorgersen E.B., Hellerud B.C., Nielsen E.W., Barratt-Due A., Fure H., Lindstad J.K., Pharo A., Fosse E., Tonnessen T.I., Johansen H.T., Castellheim A., Mollnes T.E. CD14 inhibition efficiently attenuates early inflammatory and hemostatic responses in Escherichia coli sepsis in pigs. FASEB J. 2010, 24:712-722.
51. Turner M.W., Grant C., Seymour N.D., Harvey B., Levinsky R.J. Evaluation of C3b/C3bi opsonization and chemiluminescence with selected yeasts and bacteria using sera of different opsonic potential. Immunology 1986, 58:111-115.
52. Ward P.A. The dark side of C5a in sepsis. Nat. Rev. Immunol. 2004, 4:133-142.